CAS NO: | 79350-37-1 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 453.4 |
Cas No. | 79350-37-1 |
Formula | C16H15N5O7S2 |
Synonyms | CL-284635,FK-027,FR17027 |
Solubility | insoluble in H2O; ≥46.2 mg/mL in DMSO; ≥6.88 mg/mL in EtOH |
Chemical Name | (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
Canonical SMILES | [H][C@@]1([C@@H]2NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)N(C(C(O)=O)=C(C=C)CS1)C2=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
MIC: from<0.025 to 25 μg/ml for E. coli, K. pneumoniae, and H. influenzae
Cefixime is a third generation cephalosporin antibiotic.
The cephalosporins, a class of β-lactam antibiotics, are originally derived from the fungus Acremonium.
In vitro: Previous study found that cefixime was more active than cephalexin, cefaclor, and amoxicillin against various gram-negative bacteria. Cefixime was also significantly more active than tested reference drugs against clinical isolates of Klebsiella pneumoniae, Escherichia coli, indole-positive and -negative Proteus species, Providencia species, and Neisseria gonorrhoeae. Moreover, cefixime was active against strains of K. pneumoniae, E. coli, as well as Proteus mirabilis resistant to the reference agents [1].
In vivo: The therapeutic activities of cefixime in mice infected with gram-negative bacilli were found to be far superior to the activities of cephalexin, cefaclor, and amoxicillin, but they were inferior to the activities against infection with Staphylococcus aureus [1].
Clinical trial: Previous study showed that the clinical success was observed in 94% of cefixime-treated patients. At the end of treatment, the overall eradication rate in the cefixime treatment group was 92% and ranged from 76% (cefaclor) to 98% (cefuroxime axetil) in the comparator treatment groups [2].
References:
[1] Kamimura, T. ,Kojo, H.,Matsumoto, Y., et al. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrobial Agents and Chemotherapy 25(1), 98-104 (1984).
[2] Quintiliani R. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Clin Ther. 1996 May-Jun;18(3):373-90; discussion 372.